Clinical trial
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With…
NCT00035945 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00035945 |
|---|---|
| Title | ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Collaborators | Hepasense Industry Elan Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | ISIS 14803 |
| Start date | Oct 1, 2001 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | May 8, 2002 |
| Last update posted | Dec 5, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: